However, efforts have focused on RPS19 gene addition, that if successfully translated into clinical use, would only be applicable to the minority of patients that have RPS19 haploinsufficiency, leaving most DBA patients with insufficient treatment options. This evidence concerns the gene RPS19 and Diamond-Blackfan anemia.